Alpine’s pipeline

We have a diverse pipeline of multi-targeted therapies in development for both inflammatory disease and oncology. In 2019, we completed enrollment of a Phase 1 healthy volunteer study for ALPN-101. Final data were presented at the 2020 EULAR E-Congress. ALPN-202 has NEON-1, a Phase 1 trial in advanced malignancies, now open for enrollment.